XEOMIN® (incobotulinumtoxinA):

For Upper Limb Spasticity in Adults

XEOMIN® (incobotulinumtoxinA) is approved for the treatment of upper limb spasticity in adult patients.1

How XEOMIN Works1

In adults with upper limb spasticity there is an imbalance of signals from the brain to the muscles, which causes stiffness and spasms. This can lead to abnormal arm or hand positions, uncomfortable movement, and pain.2

XEOMIN is injected into muscles to help interfere with these signals. This helps decrease muscle stiffness and improve your ability to function using the affected muscles.1

Some stiffness and spasms may still occur, but less severely.

Merz understands that a patient’s ability to manage symptoms is an important factor in the treatment of adult upper limb spasticity.

In clinical studies, XEOMIN significantly improved muscle tone compared with a nontherapeutic injection, known as a placebo, as measured at week 4 after initiating treatment.1

The Global Impression of Change Scale (GICS) is a global measure of a patient’s functional improvement. When investigators rated how much overall change in spasticity they saw in each patient following treatment with XEOMIN1:

  • 3 out of 4 patients showed at least “minimal improvement” in function with XEOMIN1
  • 43% of patients were rated as “much improved” (40%) or “very much improved” (3%) with XEOMIN1


My life. My Xeomin.

“I hope that treatment can provide more flexibility. Then maybe I could get back to doing more of the things that I did before.”
Ruben, 40, adult upper limb spasticity patient

Read more of Ruben’s story.

Ask your doctor about your neurotoxin treatment options. Ask about XEOMIN.
If you’re currently being treated for adult upper limb spasticity, know that you have options. Use this discussion guide to talk to your doctor about starting treatment with XEOMIN.


  1. XEOMIN® [package insert]. Raleigh, NC: Merz North America, Inc; 2015.
  2. Differential diagnosis for spasticity. Neuro Rehab Resource website. http://www.neurorehabresource.org/Files/NRR_Differential_Diagnosis.pdf. Accessed October 7, 2015.